Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Difficult journeys in sarcoma care; socioeconomic disparity added to the multiple challenges of a rare tumor diagnosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Agreement between the Danish Cancer Registry and the Danish Colorectal Cancer Group Database

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Meet the Acta Oncologica editorial board

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anna-Mária Tőkés
  • Orsolya Rusz
  • Gábor Cserni
  • Erika Tóth
  • Gábor Rubovszky
  • Tímea Tőkés
  • Laura Vízkeleti
  • Lilla Reiniger
  • Renáta Kószó
  • Zsuzsanna Kahán
  • Janina Kulka
  • Marco Donia
  • András Vörös
  • Zoltan Szallasi
Vis graf over relationer

Background: Chemotherapeutic agents are often mutagenic. Induction of mutation associated neo-epitopes is one of the mechanisms by which chemotherapy is thought to increase the number of tumor-infiltrating lymphocytes. It is not known, however, whether treatment with various chemotherapeutic agents with different mutagenic capacity induce a significantly different number of stromal tumor-infiltrating lymphocytes (StrTIL) in residual cancer. Methods: One hundred and twenty breast carcinoma cases with residual disease that were treated with one of three types of pre-operative chemotherapy regimens were selected for the study. The percentage of StrTIL was evaluated in pretreatment core biopsies (pre-StrTIL) and post-treatment surgical tumor samples (post-StrTIL). TIL changes (ΔStrTIL) were calculated from the difference between post-StrTIL and pre-StrTIL. Results: When analyzing the pre-StrTIL and post-StrTIL among the three treatment groups, we detected significant StrTIL increase independently of the treatment applied. Based on distant metastases-free survival analysis, both post-StrTIL and ΔStrTIL was found to be independent prognostic factor in HR negative cases. Conclusions: Significant increase of StrTIL in the residual disease was observed in patients treated with the highly (platinum), moderately (cyclophosphamide) and marginally mutagenic chemotherapeutic agents (taxane, anthracycline). Increase in StrTIL in residual cancer compared to pretreatment tumor tissue is associated with improved distant metastasis-free survival in cases with HR negative breast carcinoma.

OriginalsprogEngelsk
TidsskriftActa oncologica
Vol/bind58
Udgave nummer11
Sider (fra-til)1603-1611
Antal sider9
ISSN0284-186X
DOI
StatusUdgivet - nov. 2019

ID: 57730800